2022-10-20 | NDAQ:OPRX | Press release
The virtual event takes place on December 1, 2022
ROCHESTER, Michigan, Oct. 20, 2022 (GLOBE NEWSWIRE) — OptimizeRx Corp (the &CloseCurlyDoubleQuote Company;) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions that help patients start and continue their treatment, today announced the third annual Innovate4Outcomes® event co-sponsored by Melinta Therapeutics. This virtual event will take place on December 1, 2022. The sponsors invite participation from healthcare providers, pharmaceutical and medical technology manufacturers, healthcare marketing and advertising agencies and other industry players. life sciences industry.
Innovate4Outcomes is a half-day design think tank event that brings together those interested in interprofessional collaboration to brainstorm potential pathways to reduce the threat of systemic challenges in healthcare in the United States. This year’s challenge has been identified by the World Health Organization as one of today’s ten most pressing global health challenges: antimicrobial resistance (AMR). Antimicrobial resistance has many facets that are compounded by siloed care delivery pathways and social issues, including treatment resistance, challenges in developing new therapies, provider training, and equity. health. A recent study published in The Lancet estimated that there were approximately 5 million deaths worldwide associated with bacterial AMR in 2019, in addition to many other harmful effects on human health and longevity.
“We are thrilled to co-sponsor this event with OptimizeRx,” said Matthew Balogh, digital marketing manager, Melinta Therapeutics. the healthcare community to come together and draw on their own varied backgrounds and experiences to contribute to the conversation.”
On the day of the event, attendees will be divided into teams and learn which of the three AMR-related systemic healthcare challenges they will be assigned to. Six teams, two for each challenge, will work together to envision future approaches to this important health issue. Teams will then pitch their ideas to a panel of judges, and OptimizeRx will invest in the winning concept with the goal of creating a business case for further development.
“Our annual design thinking in healthcare event, Innovate4Outcomes, is a testament to the visionary approach we take every day working with our industry colleagues to improve awareness, access and adherence to therapies. for patients,” said Maria Cipicchio, Senior Vice President of Marketing and Communications, OptimizeRx. “Global health challenges like antimicrobial resistance are taking creative approaches to solving problems, and we host this annual event to envision a better future state of healthcare. We’re excited to be able this year to offer the opportunity to expand ongoing support to determine if we can bring the winning idea to life.”
The event is free and invitations are required to access it. Visit this link to request an invitation.
AboutOptimizeRx
OptimizeRx provides best-in-class healthcare technology that enables care-driven engagement between life science organizations, healthcare providers, and patients at critical moments throughout the patient care journey. Connecting more than 60% of US healthcare providers and millions of their patients through the smartest technology platform integrated into a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications.
For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
About Melinta Therapeutics
Melinta Therapeutics, LLC provides innovative therapies for people affected by acute and life-threatening illnesses. Our portfolio currently includes six commercial-stage products: Baxdela® (delafloxacin), Kimyrsa® (oritavancin), Minocin® (minocycline) for injection, Orbactiv® (oritavancin), TOPROL-XL® (metoprolol succinate) and Vabomere® (meropenem and vaborbactam). With an unparalleled commitment to providers and the patients they serve, we strive to ensure that everyone who needs our therapies can receive them. We focus our expanding portfolio on serving patients with unmet need, because that’s how we have the most meaningful impact. At Melinta, we are visionaries dedicated to innovation while remaining rooted in what matters most: patients. For more information, including product and respective important safety information, please visit our website.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.;, “projects”, “targets”, “designs”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify such forward-looking statements.All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact , are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performance.These forward-looking statements are based on the Company’s current expectations and assumptions regarding future business, economy and other future conditions.The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information. information, future events or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those stated, contemplated or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other risks summarized in the company’s annual report on Form 10-K for l fiscal year ended December 31, 2021, its subsequent quarterly reports on Form 10-Q and its other filings with the Securities and Exchange Commission.
Contact OptimiserRx
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Contact person for media relations
Kimberley Sirk, Media Relations Manager
ksirk@optimizerx.com
Investor Relations
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
